Brought to you by 
RedHill pens prelim deal to license IntelGenx's migraine film; later finalized; terminated
30 Mar 2018
Executive Summary
In a preliminary deal, IntelGenx Corp. (rapid- and controlled-release drug delivery technologies) has licensed spec pharmaco RedHill Biopharma Ltd. exclusive global rights to its Phase I INT008, an oral thin film for migraine. The companies hope to pen a definitive alliance by July 18, 2010.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
RedHill pens prelim deal to license IntelGenx's migraine film; later finalized; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice